Unknown PHASE2 INTERVENTIONAL 2-arm NCT02593968

Yallaferon in Chinese Population

a Multi-sites, Randomized, Parallel, Placebo-Controlled Clinical, Pilot Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection

Sponsor: Lee's Pharmaceutical Limited

Conditions HPV Infection

Interventions Placebo Recombinant Human Interferon a-2b Gel

Updated 5 times since 2017 Last updated: Oct 30, 2015 Started: Sep 30, 2015 Primary completion: Sep 30, 2016 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates HPV Infection and is currently ongoing. Lee's Pharmaceutical Limited leads this study, which shows 5 recorded versions since 2015 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Oct 2017 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2017 — Oct 2017 [monthly]

Recruiting PHASE2

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lee's Pharmaceutical Limited

Data source: Lee's Pharmaceutical Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China